Companies seeking a treatment for Alzheimer’s disease have spent an astonishing amount of money in recent decades with little to show for it. Some coming trial results are being treated as long shots in the investing and medical communities, meaning good news would have a seismic impact.
Since 1995, more than $42.5 billion has gone into enrolling thousands of patients across more than 1,000 trials. Yet to this day not a single treatment is available to cure or slow disease progression.
